Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilastobart + Retifanlimab in BRCA/PALB2 Deficient Pancreatic Cancer
NCT07765836Phase 2Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2027
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of vilastobart in pancreatic cancer (PC), sponsored by Massachusetts General Hospital. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
vilastobart
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07765836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07765836.